Search
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib]. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]
Synonyms: 1,3,5-triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-n2,n4-bis((1r)-2,2,2-trifluoro-1-methylethyl)-Ulobetasol
go.drugbank.com/drugs/DB00596Approved[L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047]
Zolmitriptan
go.drugbank.com/drugs/DB00315ApprovedInvestigational[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. … [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalCompared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity. … [A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted initially FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients.
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414] … [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalThe drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C.
Lyme disease vaccine (recombinant OspA)
go.drugbank.com/drugs/DB00045ApprovedWithdrawnIt is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.
Butenafine
go.drugbank.com/drugs/DB01091ApprovedButenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. In particular, butenafine acts to inhibit the activity of the squalene epo...
Bile acid receptor
go.drugbank.com/bio_entities/BE0001777TargetHumansin epigenomic repression, and SLC10A1/NTCP (involved in hepatic uptake of conjugated BAs). … Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA).
Synonyms: BAR